FDA, CBP seize 3 million illegal e-cigarette products worth $76 million, including GEEKBAR

Oct.23.2024
FDA, CBP seize 3 million illegal e-cigarette products worth $76 million, including GEEKBAR
The U.S. FDA and Customs and Border Protection (CBP) conducted a joint operation that resulted in the seizure of approximately 3 million unauthorised e-cigarette products with an estimated retail value of $76 million, marking the FDA's largest seizure to date. Notably, GEEKBAR was the only e-cigarette brand mentioned in the report.

The US Food and Drug Administration (FDA) announced on its website on 22 October that it had worked with US Customs and Border Protection (CBP) to administratively seize approximately 3 million unapproved e-cigarette products with an estimated retail value of $76 million. Notably, GEEKBAR was the only e-cigarette brand mentioned in the report.

 

This seizure was part of a joint operation in July to inspect inbound shipments to prevent illegal e-cigarettes from entering the U.S. It is the largest enforcement action by the FDA to date.
 

FDA, CBP seize 3 million illegal e-cigarette products worth $76 million, including GEEKBAR
The FDA has seized illegal e-cigarettes, including GEEKBAR. | Image source: FDA official website

 

The FDA and the US Department of Justice (DOJ) announced in June the creation of a joint federal task force to crack down on the illegal distribution and sale of e-cigarettes.

 

The FDA revealed that the joint team spent several months conducting extensive investigations in preparation for the operation. This included reviewing shipping invoices, identifying potentially illegal imports and gathering intelligence, all of which contributed to the success of the operation.

 

During inspections of goods arriving from China, the team uncovered numerous unauthorised e-cigarettes, including brands such as GEEKBAR. Many of these products were deliberately mis-declared as unrelated items and undervalued to avoid customs duties and detection. The seized products will now be processed in accordance with US Customs and Border Protection (CBP) regulations.

 

"The FDA is on high alert and coordinating closely with our federal partners to stop these products at the border. Many of these e-cigarettes end up in the hands of children, and the newly formed federal task force is committed to working together to combat this unethical behaviour," said FDA Commissioner Robert M. Califf.

 

Troy A. Miller, a senior official with U.S. Customs and Border Protection, reiterated the agency's commitment to protecting American consumers. "CBP places a high priority on intercepting illegal products that could cause harm. We will continue to work with our law enforcement partners to identify and seize unsafe and illegal goods."

 

"This is not our first joint seizure operation, and it certainly won't be the last. We are committed to tracking down those who attempt to smuggle illegal e-cigarettes. The fact that these criminals essentially threw $76 million in the trash should remind them that their time and money would be better spent complying with the law," said Brian King, director of the FDA's Center for Tobacco Products. 

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia will place e-cigarettes and related nicotine products under its “strategic goods” framework from August 20, 2026. According to TVP World’s report published on August 19, the newly listed items include e-cigarettes, electronic smoking devices, vape liquids and nicotine salts. Individuals who illegally move these products across Russia’s customs border or its state border with other Eurasian Economic Union (EAEU) members could face up to five years in prison if shipment values exceed 100,000 rubles (about €1,000), provided all elements of a criminal offence are established.
Aug.20
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22